Your session is about to expire
← Back to Search
Virtual Education Program for Atrial Fibrillation
N/A
Waitlist Available
Led By Anil Gehi, MD
Research Sponsored by University of North Carolina, Chapel Hill
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1-year prior to intervention session 1 and 1-year post intervention session 12
Awards & highlights
No Placebo-Only Group
Summary
This trial will assess the effectiveness of a virtual education program to help primary care providers better manage patients with AF.
Who is the study for?
This trial is for primary care providers (Physicians, Nurse Practitioners, Physician Assistants) who are based in North Carolina and manage adult patients with atrial fibrillation. There are no specific exclusion criteria mentioned, so it appears open to all eligible healthcare professionals within the state.
What is being tested?
The study tests a virtual education program called 'AF and EKG Interpretation Project ECHO' designed to improve knowledge and confidence among primary care providers managing atrial fibrillation. It involves 12 hours of Zoom sessions over twelve weeks and assessments before and after the program.
What are the potential side effects?
Since this trial focuses on an educational program rather than a medical intervention, there are no direct side effects associated with medications or treatments. However, participants may experience fatigue or eye strain from screen time.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1-year prior to intervention session 1 and 1-year post intervention session 12
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1-year prior to intervention session 1 and 1-year post intervention session 12
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change in Number of Patients Prescribed Appropriate Anticoagulation
Secondary study objectives
Change Score on Provider Knowledge Assessment
Change in Number of Emergency Department Visits or Hospitalizations for AF or Stroke
Change in Number of Patients Prescribed Appropriate Antiplatelet Therapy
+3 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: AF and EKG Interpretation Project ECHOExperimental Treatment1 Intervention
All recruited participants participate in the AF and EKG Interpretation Project ECHO educational intervention.
Find a Location
Who is running the clinical trial?
Wake Forest UniversityOTHER
192 Previous Clinical Trials
166,116 Total Patients Enrolled
1 Trials studying Atrial Fibrillation
300 Patients Enrolled for Atrial Fibrillation
University of North Carolina, Chapel HillLead Sponsor
1,569 Previous Clinical Trials
4,319,464 Total Patients Enrolled
3 Trials studying Atrial Fibrillation
935 Patients Enrolled for Atrial Fibrillation
Duke UniversityOTHER
2,463 Previous Clinical Trials
2,981,740 Total Patients Enrolled
13 Trials studying Atrial Fibrillation
13,201 Patients Enrolled for Atrial Fibrillation
Bristol-Myers SquibbIndustry Sponsor
2,696 Previous Clinical Trials
4,098,951 Total Patients Enrolled
72 Trials studying Atrial Fibrillation
1,650,900 Patients Enrolled for Atrial Fibrillation
Anil Gehi, MDPrincipal InvestigatorUniversity of North Carolina, Chapel Hill
2 Previous Clinical Trials
826 Total Patients Enrolled
2 Trials studying Atrial Fibrillation
826 Patients Enrolled for Atrial Fibrillation
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- Not applicable.
Research Study Groups:
This trial has the following groups:- Group 1: AF and EKG Interpretation Project ECHO
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.